Navan
NAVAN, Inc. (NAVAN) is an early-stage private biotechnology company developing a novel, proprietary NanoStraw platform to enable the next generation of cell and gene therapies. A non-viral physical delivery technology, NanoStraws provide direct access to the cytosol of a cell and enable the delivery of Any Cargo into Any Cell in a gentle, non-perturbative manner. High cell viability, the ability to have multiple deliveries of different cargos into a cell, and no cargo size limitations are hallmarks of the platform. Cell transformation via NanoStraws will drastically reduce the complexity, cost and technical challenges involved in cell therapy manufacturing, allowing NAVAN to actively pursue the development of innovative therapies in a broad range of indications with its strategic collaborators and partners.
Management
Dr. Craig Garner
Mr. Ryan Swoboda
Dr. Sergio Leal-Ortiz
Dr. Chris Rehse
Dr. Nick Melosh
Pressemeldungen
NAVAN Closes Seed Funding Round – Investors include Amgen Ventures, HTGF and Hemi Ventures
Info & Contact
- E-mail:
- info@navanbio.com
- Web:
- www.navanbio.com